Long read sequencing of the 16S-23S rRNA operon to characterize gut microbial changes associated with multiple sclerosis

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Assistant Professor of Neurology, Yale University
    Biography

      Dr. Longbrake earned her MD and PhD degrees at the Ohio State University and then did a fellowship in neuroimmunology at Washington University. She is currently an Assistant Professor of Neurology at Yale University, where she directs the clinical and translational research program in neuroimmunology. Her current work focuses on the relationships between the microbiome/metabolome, multiple sclerosis, and the immunomodulatory medications used to treat the disease.


    Abstract

    The microbiome has emerged as a major contributor to human health and disease. Numerous sources implicate shifts in the gut microbiome as potentially pathologic for a variety of autoimmune diseases. For many of these diseases, changes in the microbiome are subtle and descriptive in nature. Further, limitations in 16S rRNA sequencing make inter-study comparisons and identification of causative microbes difficult. This heterogeneity can be traced to the evolution of sequencing technology and variability in sampling methodology. For example, in multiple sclerosis, numerous research groups have described shifts in gut microbes among patients, but identified taxa have been inconsistent across studies. To address these challenges, we have implemented long-amplicon sequencing of the 16S-ITS-23S rRNA operon, which, when combined with machine learning-based denoising, allows reliable taxonomic resolution down to the species and strain levels, facilitating more definitive comparison between clinical cohorts and possible identification of causative microbes. Using these technologies, we set out to study the microbiomes of new-onset treatment-naïve relapsing-remitting multiple sclerosis at baseline and post B cell depletion therapy, with healthy donors as a control group. We identify Bacteroides emerge as being enriched in the gut microbiota of MS patients. This trend reverses upon initiation of effective immunomodulatory therapy for MS. Manipulation of the gut microbiome is a putative mechanism of action by which immunomodulatory therapies may impact MS and other immune-medicated diseases. Further exploration of these phenomena may open new avenues for understanding and treating MS.

    Learning Objectives:

    1. Understand the pros/cons of generating and processing long-read microbiome data

    2. Identify differences between the microbiome of healthy subjects and MS patients at baseline

    3. Understand how immunotherapy may influence the microbiome of MS patients


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    JUL 22, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 22, 2020 10:00 AM PDT
    DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    Loading Comments...
    Show Resources